 Passive monoclonal antibody therapy can ensure consistent antibody concentration, and can control for adverse reactions by stopping administration.However, the repeated administration and consequent higher cost for this therapy are major disadvantages.Monoclonal antibody therapy may prove to be beneficial for cancer, autoimmune diseases, and neurological disorders that result in the degeneration of body cells, such as Alzheimer's disease.